Replimune Group, Inc. (REPL) has 20 既知のインサイダーおよび機関投資家保有者の記録. 最大保有者は Omega Fund IV, L.P. 4,773,542 株保有. その他の主要保有者には Atlas Venture Fund X, L.P. および Coffin Robert.
過去12ヶ月間にインサイダーは 18 件の取引を実施 REPL 株式 — 5 件の買い (評価額 RSU アワード) および 12 件の売り (評価額 $962.48K). インサイダーの売りが買いを上回っています.
REPL インサイダー保有状況
最大保有者
Omega Fund IV, L.P.
4,773,542 株
インサイダー上位保有者
| # |
氏名 |
役職 |
保有株数 |
最終申告日 |
相対規模 |
| 1 |
Omega Fund Iv, L.p. |
10 Percent Owner |
4,773,542 |
2021-11-23 |
|
| 2 |
Atlas Venture Fund X, L.p. |
10 Percent Owner |
2,486,296 |
2020-09-17 |
|
| 3 |
Coffin Robert |
Director |
1,821,872 |
2024-05-20 |
|
| 4 |
Astley-sparke Philip |
Director |
1,380,071 |
2026-02-20 |
|
| 5 |
Atlas Venture Opportunity Fund I, L.p. |
Officer |
1,100,000 |
2019-11-20 |
|
| 6 |
Love Colin |
Chief Operating Officer |
777,345 |
2024-05-20 |
|
| 7 |
Patel Sushil |
Chief Executive Officer |
533,576 |
2025-12-19 |
|
| 8 |
Xynos Konstantinos |
Chief Medical Officer |
199,685 |
2025-12-19 |
|
| 9 |
Hill Emily Luisa |
Chief Financial Officer |
194,368 |
2025-12-19 |
|
| 10 |
Sarchi Christopher |
Chief Commercial Officer |
151,588 |
2026-04-06 |
|
| 11 |
Lewis Tanya |
Chief Dev. Op. Officer |
135,293 |
2023-06-15 |
|
| 12 |
Franchi Jean M. |
Chief Financial Officer |
128,748 |
2023-05-18 |
|
| 13 |
Esposito Pamela |
Chief Business Officer |
86,333 |
2023-09-13 |
|
| 14 |
Schwendenman Andrew |
Chief Accounting Officer |
78,284 |
2025-12-19 |
|
| 15 |
Gorgol Stephen A |
Chief Accounting Officer |
66,050 |
2020-04-02 |
|
| 16 |
Baker Bros. Advisors Lp |
10 Percent Owner |
64,000 |
2025-03-07 |
|
| 17 |
Kaufman Howard |
Chief Medical Officer |
58,067 |
2019-12-19 |
|
| 18 |
Balachandran Madhavan |
Director |
32,000 |
2025-04-03 |
|
| 19 |
Levitsky Hyam |
Director |
32,000 |
2024-04-03 |
|
| 20 |
Pucci Paolo |
Director |
32,000 |
2025-04-03 |
|
最近の取引 (過去12ヶ月)
| 日付 |
氏名 |
役職 |
種類 |
株数 |
株価 |
価値 |
| 2026-04-02 |
Sarchi Christopher |
Chief Commercial Officer |
情報に基づく売り |
6,500 |
$8.01 |
$52.07K |
| 2026-02-18 |
Astley-sparke Philip |
Director |
贈与（送付） |
25,000 |
- |
- |
| 2025-12-19 |
Sarchi Christopher |
Chief Commercial Officer |
RSU 付与（制限付株式） |
35,000 |
- |
- |
| 2025-12-19 |
Schwendenman Andrew |
Chief Accounting Officer |
RSU 付与（制限付株式） |
10,000 |
- |
- |
| 2025-12-19 |
Xynos Konstantinos |
Chief Medical Officer |
RSU 付与（制限付株式） |
60,000 |
- |
- |
| 2025-12-19 |
Patel Sushil |
Chief Executive Officer |
RSU 付与（制限付株式） |
200,000 |
- |
- |
| 2025-12-19 |
Hill Emily Luisa |
Chief Financial Officer |
RSU 付与（制限付株式） |
60,000 |
- |
- |
| 2025-12-09 |
Dhingra Kapil |
Director |
情報に基づく売り |
3,169 |
$10.40 |
$32.96K |
| 2025-12-02 |
Patel Sushil |
Chief Executive Officer |
情報に基づく売り |
10,000 |
$11.13 |
$111.3K |
| 2025-11-17 |
Sarchi Christopher |
Chief Commercial Officer |
情報に基づく売り |
5,208 |
$9.10 |
$47.39K |
| 2025-11-17 |
Xynos Konstantinos |
Chief Medical Officer |
情報に基づく売り |
7,248 |
$9.10 |
$65.96K |
| 2025-08-15 |
Hill Emily Luisa |
Chief Financial Officer |
情報に基づく売り |
9,154 |
$5.37 |
$49.16K |
| 2025-05-20 |
Sarchi Christopher |
Chief Commercial Officer |
情報に基づく売り |
3,749 |
$8.05 |
$30.18K |
| 2025-05-20 |
Schwendenman Andrew |
Chief Accounting Officer |
情報に基づく売り |
3,287 |
$8.05 |
$26.46K |
| 2025-05-20 |
Xynos Konstantinos |
Chief Medical Officer |
情報に基づく売り |
7,952 |
$8.06 |
$64.09K |
| 2025-05-20 |
Patel Sushil |
Chief Executive Officer |
情報に基づく売り |
25,105 |
$8.06 |
$202.35K |
| 2025-05-20 |
Hill Emily Luisa |
Chief Financial Officer |
情報に基づく売り |
2,535 |
$8.05 |
$20.41K |
| 2025-05-20 |
Astley-sparke Philip |
Director |
情報に基づく売り |
32,279 |
$8.06 |
$260.17K |
